Direct healthcare costs of patients with dyshidrotic eczema in the USA?

2021 ◽  
Vol 893 (1) ◽  
pp. 6-6
Keyword(s):  
Healthcare Costs ◽  
The Usa ◽  
Direct Healthcare Costs

MO545INSIDE ANEMIA OF CKD: ESTIMATING THE IMPACT OF POLICY INTERVENTIONS ON ANAEMIA OF CKD IN THE USA BY MICROSIMULATION MODELLING

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Lise Retat ◽  
Laura Webber ◽  
Juan Jose Garcia Sanchez ◽  
Claudia Cabrera ◽  
Susan Grandy ◽  
...  
Keyword(s):  
Healthcare Costs ◽  
Severe Anaemia ◽  
Service Planning ◽  
Microsimulation Model ◽  
Model Framework ◽  
The Us ◽  
The Usa ◽  
Direct Healthcare Costs ◽  
The Impact ◽  
Intervention Scenario

Abstract Background and Aims Anaemia is a common complication in patients with chronic kidney disease (CKD) and is associated with increased mortality, cardiovascular complications, reduced quality of life and increased use of healthcare resources. Mathematical modelling based on robust epidemiological and clinical data is a useful approach for predicting the future burden of disease and the impact of different intervention scenarios; this is important for health service planning. This analysis uses a microsimulation model, Inside ANEMIA of CKD, to predict the effects of a hypothetical intervention scenario that reduces the prevalence of anaemia of CKD on related healthcare costs in the USA from 2020 to 2025. Method A virtual cohort representing the US population was created within the Inside ANEMIA of CKD microsimulation model framework using demographics and epidemiological data drawn from the US Census Bureau, the Centers for Disease Control and Prevention, and the National Health and Nutrition Examination Survey. In the cohort, virtual individuals were ascribed an age–sex-stratified CKD status (defined by estimated glomerular filtration rate and albuminuria levels, as per international guidelines) and anaemia status (defined by haemoglobin level as mild, moderate or severe, as per WHO criteria) based on US prevalence data. Key comorbidities (type 2 diabetes, heart failure and hypertension) were also assigned, reflecting US-specific population statistics. Healthcare costs related to CKD and anaemia of CKD were taken from the published literature. The study modelled the effects on healthcare costs of a hypothetical intervention scenario in which the prevalence of moderate and severe anaemia is reduced by 20% per year from 2020 to 2025 compared with no intervention (baseline). In each scenario (i.e. intervention or baseline), the modelling analysis estimated healthcare costs related to CKD and anaemia (including inpatient, outpatient, pharmacy costs) for patients with moderate or severe anaemia of CKD. The model did not adjust for the potential costs of the intervention. Results Preliminary results predict that, with the hypothetical intervention, there could be 1.40 million fewer patients with moderate or severe anaemia of CKD in the USA in 2025 compared with no intervention (1.45 million versus 2.85 million). This represents a 49% reduction in cases of moderate or severe anaemia of CKD in 2025 with the intervention versus no intervention. The intervention is projected to lead to a reduction of approximately US$18 billion in annual direct healthcare costs in 2025 for patients with moderate or severe anaemia of CKD compared with no intervention (US$26 billion versus US$44 billion). Conclusion The Inside ANEMIA of CKD microsimulation model predicts that a hypothetical intervention which reduces the prevalence of moderate and severe anaemia of CKD would reduce direct healthcare costs. This suggests that interventions effective at reducing the prevalence of anaemia of CKD would help to reduce the economic burden on healthcare services.

Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA

2018 ◽  
Vol 37 (10) ◽  
pp. 2751-2761 ◽  
Author(s):  
Joseph F. Merola ◽  
Vivian Herrera ◽  
Jacqueline B. Palmer
Keyword(s):  
Psoriatic Arthritis ◽  
Healthcare Costs ◽  
Comorbidity Burden ◽  
The Usa ◽  
Direct Healthcare Costs

Costs associated with outpatient, emergency room and inpatient care for migraine in the USA

Cephalalgia ◽  
2011 ◽  
Vol 31 (15) ◽  
pp. 1570-1575 ◽  
Author(s):  
Ralph P Insinga ◽  
Daisy S Ng-Mak ◽  
Mary E Hanson
Keyword(s):  
Emergency Room ◽  
Healthcare Costs ◽  
Outpatient Visit ◽  
Inpatient Hospitalization ◽  
Migraine Headaches ◽  
The Us ◽  
Inpatient Hospitalizations ◽  
The Usa ◽  
Direct Healthcare Costs ◽  
Mean Cost

Background: Data on the average US costs of an outpatient visit, emergency room (ER) visit or hospitalization for migraine are scant, with the most recent available values based on healthcare charges reported from 1994 data. Methods: We estimated healthcare costs associated with outpatient and ER visits and inpatient hospitalizations related to migraine retrospectively obtained from the 2007 Medstat MarketScan Commercial Claims & Encounters database. Tabulated costs reflected payments from insurers, patients and other sources. All costs were adjusted to 2010 US dollars. Results: The estimated mean cost (95% CI) for migraine-related care per outpatient visit ( N = 680,946) was $139.88 ($139.35–140.41); per ER visit ( N = 88,128) was $775.09 ($768.10–782.09); and per inpatient hospitalization ( N = 5516) was $7317.07 ($7134.96–7499.17). The most frequently coded procedures at outpatient and ER visits were subcutaneous or intra-muscular injection, and for hospitalizations was computed tomography. Estimated annual US healthcare costs in 2010 for migraine associated with: outpatient visits were $3.2 billion, ER visits were $700 million, and inpatient hospitalizations were $375 million. Conclusions: Direct healthcare costs associated with patient visits and hospitalizations for migraine headaches have increased since previously published estimates. Further research is needed to understand the current overall healthcare cost burden per patient and within the US population.

scholarly journals Frailty Phenotype and Healthcare Costs in Women in Late Life: The SOF study

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 778-778
Author(s):  
Lisa Langsetmo ◽  
Allyson Kats ◽  
John Schousboe ◽  
Tien Vo ◽  
Brent Taylor ◽  
...  
Keyword(s):  
Healthcare Costs ◽  
Functional Limitations ◽  
Late Life ◽  
Cost Ratio ◽  
Deficit Accumulation ◽  
Frailty Phenotype ◽  
Medicare Claims ◽  
Accumulation Index ◽  
Direct Healthcare Costs ◽  
Frailty Indicator

Abstract We used data from 1324 women (mean age 83) at the 2002-2004 exam linked with their Medicare claims to determine the association of the frailty phenotype with healthcare costs. The frailty phenotype was categorized as robust, pre-frail or frail. Multimorbidity and a frailty indicator (approximating the deficit accumulation index) were derived from claims. Functional limitations were assessed by asking about difficulty performing IADL. Total direct healthcare costs were ascertained during 36 months following the exam. Compared with robust, pre-frailty and frailty were associated with higher costs after accounting for demographics, multimorbidity, functional limitations and the frailty indicator (cost ratio 1.37 [1.10-1.71] among pre-frail and 1.63 [1.28-2.08] among frail). Discrimination of high-cost (top decile) women was improved by adding the phenotype and functional limitations to a model containing demographics and the claims-based measures. Findings suggest that assessment of the phenotype may improve identification of individuals at higher risk of costly care.

scholarly journals Direct costs of overdiagnosed asthma: a longitudinal, population-based cohort study in British Columbia, Canada

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031306 ◽  
Author(s):  
Bryan Ng ◽  
Mohsen Sadatsafavi ◽  
Abdollah Safari ◽  
J Mark FitzGerald ◽  
Kate M Johnson
Keyword(s):  
Cohort Study ◽  
Resource Use ◽  
Healthcare Costs ◽  
Challenge Test ◽  
Medication Use ◽  
Population Based ◽  
Methacholine Challenge ◽  
Physician Visits ◽  
Direct Healthcare Costs ◽  
Physician Diagnosis

ObjectivesA current diagnosis of asthma cannot be objectively confirmed in many patients with physician-diagnosed asthma. Estimates of resource use in overdiagnosed cases of asthma are necessary to measure the burden of overdiagnosis and to evaluate strategies to reduce this burden. We assessed differences in asthma-related healthcare resource use between patients with a confirmed asthma diagnosis and those with asthma ruled out.DesignPopulation-based, prospective cohort study.SettingParticipants were recruited through random-digit dialling of both landlines and mobile phones in the province of British Columbia, Canada.ParticipantsWe included 345 individuals ≥12 years of age with a self-reported physician diagnosis of asthma. The diagnosis of asthma was reassessed at the end of 12 months of follow-up using a structured algorithm, which included a bronchodilator reversibility test, methacholine challenge test, and if necessary medication tapering and a second methacholine challenge test.Primary and secondary outcome measuresSelf-reported annual asthma-related direct healthcare costs (2017 Canadian dollars), outpatient physician visits and medication use from the perspective of the Canadian healthcare system.ResultsAsthma was ruled out in 86 (24.9%) participants. The average annual asthma-related direct healthcare costs for participants with confirmed asthma were $C497.9 (SD $C677.9) and for participants with asthma ruled out, $C307.7 (SD $C424.1). In the adjusted analyses, a confirmed diagnosis was associated with higher direct healthcare costs (relative ratio (RR)=1.60, 95% CI 1.14 to 2.22), increased rate of specialist visits (RR=2.41, 95% CI 1.05 to 5.40) and reliever medication use (RR=1.62, 95% CI 1.09 to 2.35), but not primary care physician visits (p=0.10) or controller medication use (p=0.11).ConclusionsA quarter of individuals with a physician diagnosis of asthma did not have asthma after objective re-evaluation. These participants still consumed a significant amount of asthma-related healthcare resources. The population-level economic burden of asthma overdiagnosis could be substantial.

Direct Healthcare Costs of Osteoporosis-Related Fractures in Managed Care Patients Receiving Pharmacological Osteoporosis Therapy

2012 ◽  
Vol 10 (3) ◽  
pp. 163-173 ◽  
Author(s):  
Hema N. Viswanathan ◽  
Jeffrey R. Curtis ◽  
Jingbo Yu ◽  
Jeffrey White ◽  
Bradley S. Stolshek ◽  
...  
Keyword(s):  
Managed Care ◽  
Healthcare Costs ◽  
Osteoporosis Therapy ◽  
Direct Healthcare Costs

scholarly journals The direct healthcare costs associated with psychological distress and major depression: A population-based cohort study in Ontario, Canada

PLoS ONE ◽  
2017 ◽  
Vol 12 (9) ◽  
pp. e0184268 ◽  
Author(s):  
Maria Chiu ◽  
Michael Lebenbaum ◽  
Joyce Cheng ◽  
Claire de Oliveira ◽  
Paul Kurdyak
Keyword(s):  
Cohort Study ◽  
Psychological Distress ◽  
Major Depression ◽  
Healthcare Costs ◽  
Population Based ◽  
Direct Healthcare Costs

Food consumption and manufacturing output

2016 ◽  
Vol 24 (4) ◽  
pp. 38-40
Author(s):  
Graham Cole
Keyword(s):  
Chronic Disease ◽  
Food Consumption ◽  
Healthcare Costs ◽  
Design Methodology ◽  
Reading Time ◽  
Well Being ◽  
Content Type ◽  
The Usa ◽  
Pertinent Information ◽  
Practical Implications

Purpose This paper aims to review the latest management developments across the globe and pinpoint practical implications from cutting-edge research and case studies. Design/methodology/approach This briefing is prepared by an independent writer who adds their own impartial comments and places the articles in context. Findings Recent decades have witnessed growing concerns about obesity and serious medical conditions. These issues are especially prominent in the USA. One significant consequence is a stronger commitment toward improving health in the workplace. It is widely accepted that positive correlation exists between employee well-being and productivity. The reverse is also true though. Chronic disease among the workforce invariably affects the organization’s ability to compete with its rivals. An inevitable rise in healthcare costs further heightens the negative fallout. Practical implications The paper provides strategic insights and practical thinking that have influenced some of the world’s leading organizations. Originality/value The briefing saves busy executives and researchers hours of reading time by selecting only the very best, most pertinent, information and presenting it in a condensed and easy-to-digest format.

Sign in / Sign up

Export Citation Format

Share Document